Estonia - Kiestonia - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 100mg 14tk; 100mg 84tk; 100mg 100tk; 100mg 21tk; 100mg 70tk; 100mg 56tk; 100mg 98tk; 100mg 112tk; 100mg 60tk; 100mg 28tk

Estonia - Kiestonia - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 150mg 56tk; 150mg 112tk; 150mg 100tk; 150mg 14tk; 150mg 98tk; 150mg 21tk; 150mg 60tk; 150mg 28tk

Estonia - Kiestonia - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 75mg 60tk; 75mg 98tk; 75mg 56tk; 75mg 70tk; 75mg 28tk; 75mg 112tk; 75mg 100tk; 75mg 84tk; 75mg 14tk

Estonia - Kiestonia - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 300mg 70tk; 300mg 14tk; 300mg 56tk; 300mg 28tk; 300mg 98tk; 300mg 60tk; 300mg 21tk; 300mg 84tk

Estonia - Kiestonia - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 50mg 28tk; 50mg 84tk; 50mg 70tk; 50mg 98tk; 50mg 14tk; 50mg 112tk; 50mg 60tk; 50mg 21tk; 50mg 100tk; 50mg 56tk

Estonia - Kiestonia - Ravimiamet

orion corporation - pregabaliin - kõvakapsel - 25mg 28tk; 25mg 70tk; 25mg 98tk; 25mg 56tk; 25mg 21tk; 25mg 84tk; 25mg 60tk; 25mg 14tk

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastilised ained - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

diurnal europe b.v. - hüdrokortisoon - adrenal hyperplasia, congenital - kortikosteroidid süsteemseks kasutamiseks - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - avandamet on näidustatud ravi 2. tüüpi suhkurtõve patsientidel, eriti ülekaalulistel patsientidel:kellel ei ole võimalik saavutada piisavat glycaemic kontrolli nende maksimaalne talutav annus suuline metformiin üksi. triple suukaudne ravi sulphonylurea patsientidel, kellel on ebapiisav glycaemic kontrolli hoolimata dual suukaudne ravi nende maksimaalne talutav annus metformiin ja sulphonylurea (vt lõik 4.